| Peak Physical Therapy & Sports Rehab | |
|
1302 Prospect Ave Ste C, Helena, MT 59601-3928 | |
| (406) 502-1900 | |
| (406) 502-1333 |
| Full Name | Peak Physical Therapy & Sports Rehab |
|---|---|
| Type | Facility |
| Speciality | Physical Therapist |
| Location | 1302 Prospect Ave Ste C, Helena, Montana |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033583273 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | (* (Not Available)) | Primary |
| Provider Name | Jennell L Day |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1316225865 PECOS PAC ID: 3870728751 Enrollment ID: I20140523002092 |
News Archive
Researchers working with Iraq and Afghanistan war veterans have found that post-traumatic stress disorder, the current most common mental disorder among veterans returning from service in the Middle East, is associated with an increased risk for thoughts of suicide.
ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a US $11 million series B investment. The financing round was led by new investor Gilde Healthcare Partners, a leading European life sciences investor, who joins existing investor Index Ventures. Dirk Kersten from Gilde will join the company's Supervisory Board.
The National Institutes of Health plans to invest at least $100 million over the next four years toward an audacious goal: develop affordable, gene-based cures for sickle cell disease and HIV.
AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV).
› Verified 8 days ago
| Provider Name | Noah Eshleman |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1912355454 PECOS PAC ID: 5092001529 Enrollment ID: I20160909001936 |
News Archive
Researchers working with Iraq and Afghanistan war veterans have found that post-traumatic stress disorder, the current most common mental disorder among veterans returning from service in the Middle East, is associated with an increased risk for thoughts of suicide.
ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a US $11 million series B investment. The financing round was led by new investor Gilde Healthcare Partners, a leading European life sciences investor, who joins existing investor Index Ventures. Dirk Kersten from Gilde will join the company's Supervisory Board.
The National Institutes of Health plans to invest at least $100 million over the next four years toward an audacious goal: develop affordable, gene-based cures for sickle cell disease and HIV.
AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV).
› Verified 8 days ago
| Provider Name | Cory W Murray |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1760921357 PECOS PAC ID: 1759665185 Enrollment ID: I20170303001018 |
News Archive
Researchers working with Iraq and Afghanistan war veterans have found that post-traumatic stress disorder, the current most common mental disorder among veterans returning from service in the Middle East, is associated with an increased risk for thoughts of suicide.
ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a US $11 million series B investment. The financing round was led by new investor Gilde Healthcare Partners, a leading European life sciences investor, who joins existing investor Index Ventures. Dirk Kersten from Gilde will join the company's Supervisory Board.
The National Institutes of Health plans to invest at least $100 million over the next four years toward an audacious goal: develop affordable, gene-based cures for sickle cell disease and HIV.
AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV).
› Verified 8 days ago
| Provider Name | Brooke Darfler |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1053831446 PECOS PAC ID: 0244501377 Enrollment ID: I20170807003423 |
News Archive
Researchers working with Iraq and Afghanistan war veterans have found that post-traumatic stress disorder, the current most common mental disorder among veterans returning from service in the Middle East, is associated with an increased risk for thoughts of suicide.
ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a US $11 million series B investment. The financing round was led by new investor Gilde Healthcare Partners, a leading European life sciences investor, who joins existing investor Index Ventures. Dirk Kersten from Gilde will join the company's Supervisory Board.
The National Institutes of Health plans to invest at least $100 million over the next four years toward an audacious goal: develop affordable, gene-based cures for sickle cell disease and HIV.
AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV).
› Verified 8 days ago
| Provider Name | Jonathan Zachary Aldrich |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1730670324 PECOS PAC ID: 3375890064 Enrollment ID: I20180726001967 |
News Archive
Researchers working with Iraq and Afghanistan war veterans have found that post-traumatic stress disorder, the current most common mental disorder among veterans returning from service in the Middle East, is associated with an increased risk for thoughts of suicide.
ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a US $11 million series B investment. The financing round was led by new investor Gilde Healthcare Partners, a leading European life sciences investor, who joins existing investor Index Ventures. Dirk Kersten from Gilde will join the company's Supervisory Board.
The National Institutes of Health plans to invest at least $100 million over the next four years toward an audacious goal: develop affordable, gene-based cures for sickle cell disease and HIV.
AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV).
› Verified 8 days ago
| Provider Name | Danielle Williams |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1922558675 PECOS PAC ID: 6507265147 Enrollment ID: I20210601002356 |
News Archive
Researchers working with Iraq and Afghanistan war veterans have found that post-traumatic stress disorder, the current most common mental disorder among veterans returning from service in the Middle East, is associated with an increased risk for thoughts of suicide.
ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a US $11 million series B investment. The financing round was led by new investor Gilde Healthcare Partners, a leading European life sciences investor, who joins existing investor Index Ventures. Dirk Kersten from Gilde will join the company's Supervisory Board.
The National Institutes of Health plans to invest at least $100 million over the next four years toward an audacious goal: develop affordable, gene-based cures for sickle cell disease and HIV.
AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV).
› Verified 8 days ago
| Provider Name | Jesse N Bostrom |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1952079543 PECOS PAC ID: 8820494933 Enrollment ID: I20210914003313 |
News Archive
Researchers working with Iraq and Afghanistan war veterans have found that post-traumatic stress disorder, the current most common mental disorder among veterans returning from service in the Middle East, is associated with an increased risk for thoughts of suicide.
ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a US $11 million series B investment. The financing round was led by new investor Gilde Healthcare Partners, a leading European life sciences investor, who joins existing investor Index Ventures. Dirk Kersten from Gilde will join the company's Supervisory Board.
The National Institutes of Health plans to invest at least $100 million over the next four years toward an audacious goal: develop affordable, gene-based cures for sickle cell disease and HIV.
AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV).
› Verified 8 days ago
| Provider Name | Haley A Hodenfield |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1760136816 PECOS PAC ID: 5597159178 Enrollment ID: I20220224001051 |
News Archive
Researchers working with Iraq and Afghanistan war veterans have found that post-traumatic stress disorder, the current most common mental disorder among veterans returning from service in the Middle East, is associated with an increased risk for thoughts of suicide.
ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a US $11 million series B investment. The financing round was led by new investor Gilde Healthcare Partners, a leading European life sciences investor, who joins existing investor Index Ventures. Dirk Kersten from Gilde will join the company's Supervisory Board.
The National Institutes of Health plans to invest at least $100 million over the next four years toward an audacious goal: develop affordable, gene-based cures for sickle cell disease and HIV.
AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV).
› Verified 8 days ago
| Provider Name | Trevor M Morrow |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1275288458 PECOS PAC ID: 0446644066 Enrollment ID: I20220224002747 |
News Archive
Researchers working with Iraq and Afghanistan war veterans have found that post-traumatic stress disorder, the current most common mental disorder among veterans returning from service in the Middle East, is associated with an increased risk for thoughts of suicide.
ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a US $11 million series B investment. The financing round was led by new investor Gilde Healthcare Partners, a leading European life sciences investor, who joins existing investor Index Ventures. Dirk Kersten from Gilde will join the company's Supervisory Board.
The National Institutes of Health plans to invest at least $100 million over the next four years toward an audacious goal: develop affordable, gene-based cures for sickle cell disease and HIV.
AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV).
› Verified 8 days ago
| Provider Name | Keely Hutchens |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1396360830 PECOS PAC ID: 7517380744 Enrollment ID: I20220328002073 |
News Archive
Researchers working with Iraq and Afghanistan war veterans have found that post-traumatic stress disorder, the current most common mental disorder among veterans returning from service in the Middle East, is associated with an increased risk for thoughts of suicide.
ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a US $11 million series B investment. The financing round was led by new investor Gilde Healthcare Partners, a leading European life sciences investor, who joins existing investor Index Ventures. Dirk Kersten from Gilde will join the company's Supervisory Board.
The National Institutes of Health plans to invest at least $100 million over the next four years toward an audacious goal: develop affordable, gene-based cures for sickle cell disease and HIV.
AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV).
› Verified 8 days ago
| Provider Name | Cody N Cooper |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1013609650 PECOS PAC ID: 9638536725 Enrollment ID: I20230605002994 |
News Archive
Researchers working with Iraq and Afghanistan war veterans have found that post-traumatic stress disorder, the current most common mental disorder among veterans returning from service in the Middle East, is associated with an increased risk for thoughts of suicide.
ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a US $11 million series B investment. The financing round was led by new investor Gilde Healthcare Partners, a leading European life sciences investor, who joins existing investor Index Ventures. Dirk Kersten from Gilde will join the company's Supervisory Board.
The National Institutes of Health plans to invest at least $100 million over the next four years toward an audacious goal: develop affordable, gene-based cures for sickle cell disease and HIV.
AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Peak Physical Therapy & Sports Rehab Po Box 5718, Kalispell, MT 59903-5718 Ph: (406) 756-0134 | Peak Physical Therapy & Sports Rehab 1302 Prospect Ave Ste C, Helena, MT 59601-3928 Ph: (406) 502-1900 |
News Archive
Researchers working with Iraq and Afghanistan war veterans have found that post-traumatic stress disorder, the current most common mental disorder among veterans returning from service in the Middle East, is associated with an increased risk for thoughts of suicide.
ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a US $11 million series B investment. The financing round was led by new investor Gilde Healthcare Partners, a leading European life sciences investor, who joins existing investor Index Ventures. Dirk Kersten from Gilde will join the company's Supervisory Board.
The National Institutes of Health plans to invest at least $100 million over the next four years toward an audacious goal: develop affordable, gene-based cures for sickle cell disease and HIV.
AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV).
› Verified 8 days ago
Sierra Richmond, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 3345 Colton Dr Ste A, Helena, MT 59602 Phone: 406-513-1422 | |
Cody N Cooper, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1302 Prospect Ave Ste C, Helena, MT 59601 Phone: 406-502-1900 Fax: 406-502-1333 | |
Stephanie Ridgley, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2555 E Broadway St, Helena, MT 59601 Phone: 406-447-1651 | |
Mr. Mark James Bennett, P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 2525 Colonial Dr, Suite B, Helena, MT 59601 Phone: 406-449-4279 Fax: 406-449-8043 | |
Margaret Karen Koenig, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 22 N Last Chance Gulch, Helena, MT 59601 Phone: 406-502-1783 Fax: 406-502-1783 | |
Mr. Michael Joseph Arnold, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 251 Saddle Drive, Helena, MT 59601 Phone: 406-457-0480 Fax: 406-457-0481 |